<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> is a common <z:e sem="disease" ids="C0850639" disease_type="Neoplastic Process" abbrv="">premalignant lesion</z:e> caused partly by <z:e sem="disease" ids="C0017168" disease_type="Disease or Syndrome" abbrv="GERD">acid reflux</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>Although the requisite therapy, <z:chebi fb="0" ids="49200">proton pump inhibitors</z:chebi> (<z:chebi fb="4" ids="53266">PPIs</z:chebi>), have been implicated in the progression of <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> in animal models, harmful effects of prolonged <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> is both inconclusive and controversial </plain></SENT>
<SENT sid="2" pm="."><plain>We therefore aimed to test the role of <z:chebi fb="4" ids="53266">PPI</z:chebi>-induced hypergastrinaemia in vitro and see whether any biological parameters were useful surrogates of long-term therapy in man </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS: We undertook detailed serological and tissue assessment of gastrin and CCK(2) receptors in 90 patients randomised to different doses of <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy during a detailed 2-year follow-up </plain></SENT>
<SENT sid="4" pm="."><plain>We also undertook a comprehensive study of cell models to study the consequential biological effects of gastrin on the mucosa </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: Gastrin and its cognate receptor CCK(2)R were expressed highest in the stomach, then less in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> and least in squamous oesophagus (SqE) (n=20 paired t-test, p&lt;0.01) </plain></SENT>
<SENT sid="6" pm="."><plain>Analysis of the change in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> segment length change in 70 patients who were randomised to high or low <z:chebi fb="4" ids="53266">PPI</z:chebi> dose showed no difference over 2 years (n=70 t-test, p=0.8) </plain></SENT>
<SENT sid="7" pm="."><plain>Prolonged <z:chebi fb="4" ids="53266">PPI</z:chebi> use did, however, increase the serum gastrin, (36 pg/ml+/-57 pg/ml to 103 pg/ml+/-94 pg/ml (paired t test, p&lt;0.05)) </plain></SENT>
<SENT sid="8" pm="."><plain>In vitro gastrin also induced changes in OE33(E)(cckr) <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> cells, but not OE21(E)(cckr) squamous cells, transfected with CCK(2)R; migration was induced by 1 ng/ml of gastrin but proliferation only increased with 100 ng/ml (paired t-test, p&lt;0.01) and both were abolished by <z:chebi fb="68" ids="48706">antagonists</z:chebi> </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: While the short-term effects of gastrin enhance epithelial restitution in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> (but not squamous mucosa) there is no clinical evidence that <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e> length expands over time </plain></SENT>
<SENT sid="10" pm="."><plain>This study, which is the largest and longest term randomised controlled trial of gastrin biology in <z:e sem="disease" ids="C0004763" disease_type="Disease or Syndrome" abbrv="CELLO">Barrett's oesophagus</z:e>, is further proof of the clinical safety of <z:chebi fb="4" ids="53266">PPI</z:chebi> therapy </plain></SENT>
</text></document>